Literature DB >> 26320810

Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010.

Alexander P Cole1, Deepansh Dalela2, Julian Hanske1, Stephanie A Mullane3, Toni K Choueiri3, Christian P Meyer1, Paul L Nguyen4, Mani Menon2, Adam S Kibel1, Mark A Preston1, Joaquim Bellmunt3, Quoc-Dien Trinh5.   

Abstract

INTRODUCTION AND
OBJECTIVE: The importance of pelvic lymphadenectomy (LND) for diagnostic and therapeutic purposes at the time of radical cystectomy (RC) for bladder cancer is well documented. Although some debate remains on the optimal number of lymph nodes removed, 10 nodes has been proposed as constituting an adequate LND. We used data from the Surveillance, Epidemiology, and End Results database to examine predictors and temporal trends in the receipt of an adequate LND at the time of RC for bladder cancer.
MATERIAL AND METHODS: Within the Surveillance, Epidemiology, and End Results database, we extracted data on all patients with nonmetastatic bladder cancer receiving RC in the years 1988 to 2010. First, we assess the proportion of individuals undergoing RC who received an adequate LND (≥10 nodes removed) over time. Second, we calculate odds ratios (ORs) of receiving an adequate LND using logistic regression modeling to compare study periods. Covariates included sex, race, age, region, tumor stage, urban vs. rural location, and insurance status.
RESULTS: Among the 5,696 individuals receiving RC during the years 1988 to 2010, 2,576 (45.2%) received an adequate LND. Over the study period, the proportion of individuals receiving an adequate LND increased from 26.4% to 61.3%. The odds of receiving an adequate LND increased over the study period; a patient undergoing RC in 2008 to 2010 was over 4-fold more likely to receive an adequate LND relative to a patient treated in 1988 to 1991 (OR = 4.63, 95% CI: 3.32-6.45). In addition to time of surgery, tumor stage had a positive association with receipt of adequate LND (OR = 1.49 for stage IV [T4 N1 or N0] vs. stage I [T1 or Tis], 95% CI: 1.22-1.82). Age, sex, marital status, and race were not significant predictors of adequate LND.
CONCLUSION: Adequacy of pelvic LND remains an important measure of surgical quality in bladder cancer. Our data show that over the years 1988 to 2010, the likelihood of receiving an adequate LND has increased substantially; however, a substantial minority of patients still does not receive LND. Further study into factors leading to adequate LND is needed to increase the use of this important technique.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Epidemiology; Health services research; Lymph node dissection; Lymphadenectomy; Quality improvement; Radical cystectomy; Urothelial carcinoma of urinary bladder

Mesh:

Year:  2015        PMID: 26320810     DOI: 10.1016/j.urolonc.2015.07.015

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  7 in total

1.  Lymph node dissection during radical cystectomy following prior radiation therapy: results from the SEER database.

Authors:  Mahir Maruf; Abhinav Sidana; Stephanie Purnell; Amit L Jain; Sam J Brancato; Piyush K Agarwal
Journal:  Int Urol Nephrol       Date:  2017-12-23       Impact factor: 2.370

2.  Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era.

Authors:  Sean A Fletcher; Sabrina S Harmouch; Marieke J Krimphove; Alexander P Cole; Sebastian Berg; Philipp Gild; Mark A Preston; Guru P Sonpavde; Adam S Kibel; Maxine Sun; Toni K Choueiri; Quoc-Dien Trinh
Journal:  World J Urol       Date:  2018-06-14       Impact factor: 4.226

Review 3.  Lymph node dissection in bladder cancer: Where do we stand?

Authors:  Cory M Hugen; Siamak Daneshmand
Journal:  World J Urol       Date:  2015-12-28       Impact factor: 4.226

4.  Rural-urban differences in surgical treatment, regional lymph node examination, and survival in endometrial cancer patients.

Authors:  Whitney E Zahnd; Katherine S Hyon; Paula Diaz-Sylvester; Sonya R Izadi; Graham A Colditz; Laurent Brard
Journal:  Cancer Causes Control       Date:  2017-12-27       Impact factor: 2.506

Review 5.  Optimal Management of Upper Tract Urothelial Carcinoma: Current Perspectives.

Authors:  Jeffrey J Leow; Zhenbang Liu; Teck Wei Tan; Yee Mun Lee; Eu Kiang Yeo; Yew-Lam Chong
Journal:  Onco Targets Ther       Date:  2020-01-06       Impact factor: 4.147

Review 6.  The evolving role of lymphadenectomy for bladder cancer: why, when, and how.

Authors:  Vignesh T Packiam; Matvey Tsivian; Stephen A Boorjian
Journal:  Transl Androl Urol       Date:  2020-12

Review 7.  The Role of Lymph Node Dissection in the Treatment of Bladder Cancer.

Authors:  Francesco Cattaneo; Giovanni Motterle; Filiberto Zattoni; Alessandro Morlacco; Fabrizio Dal Moro
Journal:  Front Surg       Date:  2018-10-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.